Combining radiation and immunotherapy for synergistic antitumor therapy

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 1, 2009, Pages 37-42

  Ferrara, T A ^a   Hodge, J W ^a   Gulley, J L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Immunopotentiation; Radiotherapy; Therapeutic vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LC 9018; LEXIDRONAM SAMARIUM SM 153; METRONIDAZOLE; RECOMBINANT VACCINE; SAMARIUM 153; STRONTIUM 89;

ANTINEOPLASTIC ACTIVITY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL DEATH; CLINICAL TRIAL; COLON CANCER; DENDRITIC CELL; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LUNG CANCER; PROSTATE CANCER; PROSTATE CARCINOMA; RADIATION DOSE; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 58849107200     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY et al: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 7(5):1181-1191.
2. Liao YP, Schaue D, McBride WH: Modification of the tumor microenvironment to enhance immunity. Front Biosci (2007) 12:3576-3600.
3. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL et al: Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 68(12):1319-1329.
4. Friedman EJ: Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des (2002) 8(19):1765-1780.
5. Schwartz RH: T cell anergy. Annu Rev Immunol (2003) 21:305-334.
6. Hodge JW, Guha C, Neefjes J, Gulley JL: Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (2008) 22(9):1064-1070; discussion 1075, 1080-1081, 1084. • This review focuses on phenotypic modulation of tumors by radiation, and the potential synergy of radiation and vaccine combination treatments.
7. Demaria S, Bhardwaj N, McBride WH, Formenti SC: Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys (2005) 63(3):655-666. • A review of the potential synergy of radiation with immunotherapy, focusing on the ability of radiation to induce inflammation and kill tumor cells, thus releasing antigens to the immune system.
8. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G: Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol (2008) 20(5):504-511.
9. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P et al: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 13(5):1493-1502. •• A groundbreaking study that demonstrated radiation alone can induce or augment antitumor immune responses.
10. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH: T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 14(15):4883-4890.
11. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C: Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol (2006) 45(4):493-497. • An interesting clinical trial that showed the abscopal effect and regression of non-irradiated tumors.
12. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai Y et al: Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity (1994) 1(5):357-364.
13. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H: Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy. Cancer Gene Ther (2004) 11(10):665-680.
14. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 170(12):6338-6347.
15. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 64(21):7985-7994. • A preclinical study that demonstrated human tumor cells subjected to sublethal radiation in vitro were more easily killed by T-cells.
16. Zong ZW, Cheng TM, Su YP, Ran XZ, Li N, Ai GP, Xu H: Crucial role of SDF-1/CXCR4 interaction in the recruitment of transplanted dermal multipotent cells to sublethally irradiated bone marrow. J Radiat Res (2006) 47(3-4):287-293.
17. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 203(5):1259-1271. • This study demonstrated that radiation markedly affected the phenotype of tumor cells, leading to improved antitumor immunotherapy.
18. Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW: The use of chelated radionuclide (samarium-153-ethylene-diaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 14(13):4241-4249.
19. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 64(12):4328-4337.
20. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW: Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother (2008) 57(8):1173-1183. • A preclinical model that showed phenotypic changes and improved survival in a tumor therapy model following combination treatment with radiation and vaccine. This study also demonstrated that memory T-cells were not negatively affected by radiation.
21. Kudo-Saito C, Schlom J, Hodge JW: Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 11(6):2416-2426.
22. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 170(10):4905-4913.
23. Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R: Differential sensitivity of naïve and memory CD8+ T cells to apoptosis in vivo. J Immunol (2002) 169(7):3760-3770.
24. Sega EI, Lu Y, Ringor M, Leamon CP, Low PS: Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy. Int J Radiat Oncol Biol Phys (2008) 71(2):559-566.
25. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K et al: Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 11(9):3353-3362. • A clinical trial that showed immune responses can be developed in patients receiving vaccine, despite their exposure to radiation therapy.
26. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL: Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 14(16):5284-5291.
27. Okawa T, Kita M, Arai T, Iida K, Dokiya T, Takegawa Y, Hirokawa Y, Yamazaki K, Hashimoto S: Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Its effect on tumor reduction and histology. Cancer (1989) 64(9):1769-1776.
28. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (2005) 28(2):129-135. • A clinical trial that showed immune responses can be generated when immunotherapy is administered in conjunction with local radiotherapy.
29. Wang YS, Tsang YW, Chi CH, Chang CC, Chu RM, Chi KH: Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett (2008) 266(2):275-285.
30. 153Sm-EDTMP (Quadramet) with or without a PSA TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer. National Cancer Institute, Bethesda, MD, USA (2008). http://bethesdatrials.cancer.gov/ clinical-research/search-detail.aspx?ProtocolID=NCI-07-C-0106